William Blair Initiates Coverage On Cytokinetics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Outperform rating.
Stocks · News reference
Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE)
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cytokinetics Q2 2026 Earnings Call: Complete Transcript
On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113